679 related articles for article (PubMed ID: 30840024)
1. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
Mani P; Puri R; Schwartz GG; Nissen SE; Shao M; Kastelein JJP; Menon V; Lincoff AM; Nicholls SJ
JAMA Cardiol; 2019 Apr; 4(4):314-320. PubMed ID: 30840024
[TBL] [Abstract][Full Text] [Related]
2. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Nicholls SJ; Kastelein JJ; Schwartz GG; Bash D; Rosenson RS; Cavender MA; Brennan DM; Koenig W; Jukema JW; Nambi V; Wright RS; Menon V; Lincoff AM; Nissen SE;
JAMA; 2014 Jan; 311(3):252-62. PubMed ID: 24247616
[TBL] [Abstract][Full Text] [Related]
3. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
Rosenson RS; Hislop C; Elliott M; Stasiv Y; Goulder M; Waters D
J Am Coll Cardiol; 2010 Sep; 56(14):1079-88. PubMed ID: 20863951
[TBL] [Abstract][Full Text] [Related]
4. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.
Schwartz GG; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Nicholls SJ; Olsson AG; Shah PK; Tardif JC; Kittelson J
JAMA Cardiol; 2018 Feb; 3(2):164-168. PubMed ID: 29071331
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.
Fanola CL; Morrow DA; Cannon CP; Jarolim P; Lukas MA; Bode C; Hochman JS; Goodrich EL; Braunwald E; O'Donoghue ML
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066436
[TBL] [Abstract][Full Text] [Related]
6. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
Bergmark BA; Udell JA; Morrow DA; Cannon CP; Steen DL; Jarolim P; Budaj A; Hamm C; Guo J; Im K; Kuder JF; Braunwald E; Sabatine MS; O'Donoghue ML
JAMA Cardiol; 2018 Jun; 3(6):473-480. PubMed ID: 29710336
[TBL] [Abstract][Full Text] [Related]
7. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Bittner VA; Szarek M; Aylward PE; Bhatt DL; Diaz R; Edelberg JM; Fras Z; Goodman SG; Halvorsen S; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Moriarty PM; Moryusef A; Pordy R; Roe MT; Sinnaeve P; Tsimikas S; Vogel R; White HD; Zahger D; Zeiher AM; Steg PG; Schwartz GG;
J Am Coll Cardiol; 2020 Jan; 75(2):133-144. PubMed ID: 31948641
[TBL] [Abstract][Full Text] [Related]
8. Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Hagström E; Roe MT; Hafley G; Neely ML; Sidhu MS; Winters KJ; Prabhakaran D; White HD; Armstrong PW; Fox KA; Ohman EM; Boden WE;
Clin Cardiol; 2016 Jun; 39(6):329-37. PubMed ID: 27177240
[TBL] [Abstract][Full Text] [Related]
9. Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.
Puri R; Nissen SE; Arsenault BJ; St John J; Riesmeyer JS; Ruotolo G; McErlean E; Menon V; Cho L; Wolski K; Lincoff AM; Nicholls SJ
JAMA Cardiol; 2020 Oct; 5(10):1136-1143. PubMed ID: 32639518
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
[TBL] [Abstract][Full Text] [Related]
11. The residual risk of inflammation and remnant cholesterol in acute coronary syndrome patients on statin treatment undergoing percutaneous coronary intervention.
Liao J; Qiu M; Su X; Qi Z; Xu Y; Liu H; Xu K; Wang X; Li J; Li Y; Han Y
Lipids Health Dis; 2024 Jun; 23(1):172. PubMed ID: 38849939
[TBL] [Abstract][Full Text] [Related]
12. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
Hwang YC; Morrow DA; Cannon CP; Liu Y; Bergenstal R; Heller S; Mehta C; Cushman W; Bakris GL; Zannad F; White WB
Diabetes Obes Metab; 2018 Mar; 20(3):654-659. PubMed ID: 29064626
[TBL] [Abstract][Full Text] [Related]
13. High high-sensitivity C-reactive protein/BMI ratio predicts future adverse outcomes in patients with acute coronary syndrome.
Jia L; Yuan JQ; Zhu L; Zhang Y
Coron Artery Dis; 2019 Sep; 30(6):448-454. PubMed ID: 31386638
[TBL] [Abstract][Full Text] [Related]
14. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
Nicholls SJ; Nelson AJ; Lincoff AM; Brennan D; Ray KK; Cho L; Menon V; Li N; Bloedon L; Nissen SE
JAMA Cardiol; 2024 Mar; 9(3):245-253. PubMed ID: 38231501
[TBL] [Abstract][Full Text] [Related]
15. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial.
Salahuddin T; Kittelson J; Tardif JC; Shah PK; Olsson AG; Nicholls SJ; Leitersdorf E; Leiter LA; Kallend D; Black DM; Barter PJ; Ballantyne CM; Schwartz GG
Am Heart J; 2020 Mar; 221():60-66. PubMed ID: 31927126
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
Nicholls SJ; Cavender MA; Kastelein JJ; Schwartz G; Waters DD; Rosenson RS; Bash D; Hislop C
Cardiovasc Drugs Ther; 2012 Feb; 26(1):71-5. PubMed ID: 22109255
[TBL] [Abstract][Full Text] [Related]
17. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death.
Scirica BM; Cannon CP; Sabatine MS; Jarolim P; Sloane S; Rifai N; Braunwald E; Morrow DA;
Clin Chem; 2009 Feb; 55(2):265-73. PubMed ID: 19074516
[TBL] [Abstract][Full Text] [Related]
18. High-sensitivity C-reactive protein predicts adverse outcomes after non-ST-segment elevation acute coronary syndrome regardless of GRACE risk score, but not after ST-segment elevation myocardial infarction.
Raposeiras Roubín S; Barreiro Pardal C; Roubín-Camiña F; Ocaranza Sanchez R; Alvarez Castro E; Paradela Dobarro B; García-Acuña JM; Aguiar Souto P; Jacquet Hervet M; Castromán MJ; Arufe I; Outes B; Reino-Maceiras MV; Abu Assi E; González-Juanatey JR
Rev Port Cardiol; 2013 Feb; 32(2):117-22. PubMed ID: 23337430
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal High-Sensitivity C-Reactive Protein and Longer-Term Cardiovascular Outcomes in Optimally-Treated Patients With High-Risk Vascular Disease.
Dykun I; Clark D; Carlo J; Lincoff AM; Menon V; Nissen SE; Nicholls SJ; Puri R
Am J Cardiol; 2022 Oct; 181():1-8. PubMed ID: 35970631
[TBL] [Abstract][Full Text] [Related]
20. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.
Cavusoglu E; Ruwende C; Chopra V; Yanamadala S; Eng C; Pinsky DJ; Marmur JD
Coron Artery Dis; 2009 Mar; 20(2):112-7. PubMed ID: 19240644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
